Comparison of tolterodine and Solifancine in treatment of female with overactive bladder
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20212140Keywords:
Urinary incontinence, Overactive bladder, Tolterodine, SolifenacineAbstract
Background: OAB (overactive bladder) is primarily a neuromuscular problem in which the detrusor muscle contracts inappropriately during bladder filling (i.e., storage phase). These contractions often occur regardless of the amount of urine in the bladder. The aim of this work is to study the effect of Solifenacin in comparison to Tolterodine in treatment of females with idiopathic over active bladder.
Methods: This study included 50 patients who presented between March 2020 and February2021 to the outpatients clinic at El-Shatby maternity Hospital, Alexandria university. The patients were complaining of urinary urgency usually with urinary frequency, nocturia with or without urge incontinence. All cases were divided in two groups one of them receive Solifenacin5mg twice daily and the otherreceiveTolterodine2mg twice daily.
Results: Both groups showed significant decrease in frequency number per day with p value <0.001ingroup I with Solifenacin which mean statistically significant difference between two groups. When the percentage of symptoms severity were compared between both groups, group 1 showed 53% reduction in symptoms severity while group II showed 6.67% reduction which cleared significant difference statistically in group I (p=0.001). The percentage of reduction of severity of symptoms was compared between the two groups, it showed about 60%reduction in symptoms severity in group 1while in group II only 9.7% reduction. This was statistically significant with (p<0.001) in group I with Solifenacin.
Conclusions: This study suggests that Solifenacin10mg/day is more effective than Tolterodine4mg/day in reducing OAB incontinence episodes.
References
Blok BF, Willemsen AT, Holstege G. A PET study on brain control of micturition in humans. Brain. 1997;120( Pt 1):111-21.
Osman NI, Chapple CR. Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches. Arab J Urol. 2013;11(4):313-8.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
Shaw C, Matthews RJ, Perry SI, Williams K, Spiers N, Assassa RP, et al. Validity and reliability of a questionnaire to measure the impact of lower urinary tract symptoms on quality of life: the Leicester Impact Scale. Neurourol Urodyn. 2004;23(3):229-36.
Lucas MG, Bedretdinova D, Berghmans LC, Bosch JL, Burkhard FC, Cruz F, et al. Guidelines onurinary incontinence. European Association of Urology. 2015. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Urinary-Incontinence-2015.pdf. Accessed on 20th October 2019.
Patel BN, Kobashi KC. Practical use of the new American Urological Association adult urodynamics guidelines. Curr Urol Rep. 2013;14(3):240-6.
Cooper MA, Fletter PC, Zaszczurynski PJ, Damaser MS. Comparison of air-charged and water-filled urodynamic pressure measurement catheters. Neurourol Urodyn. 2011;30(3):329-34.
Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105-8.
Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT. Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract. 2009;10:8.
Kotz S, Balakrishnan N, Read CB, Vidakovic B. Encyclopedia of statistical sciences. Hoboken, N.J.: Wiley-Interscience. 2006.
Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning. 2013.
Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S565-73.
Nazir J, Kelleher C, Aballea S, Maman K, Hakimi Z, Mankowski C, et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourol Urodyn. 2018;37(3):986-96.
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:Cd005429.
Hallaz MM, Yasmeen B, Sultana N, Akter M, Basher N. Comparison of the efficacy of Solifenacin Succinate and Tolterodine for the treatment of overactive bladder syndrome. NIMCJ. 2017;8(2):231-4.
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48(3):464-70.
Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000;56(5):766-71.
Ammi M, Chautard D, Brassart E, Culty T, Azzouzi AR, Bigot P. Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder. Int Urogynecol J. 2014;25(8):1065-9.
Vandoninck V, van Balken MR, Finazzi Agro E, Petta F, Micali F, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 2003;22(3):227-32.
Basra R, Basra H, Khullar V, Kelleher C. Prescribiing antimuscarinics for overactive bladder; how many chances do we have to get it right? Int Urogynecol J. 2010;21:S139-40.
Chancellor MB, Yehoshua A, Waweru C, Globe D, Cheng IN, Campbell KL, et al. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Int Urol Nephrol. 2016;48(7):1029-36.
Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816.
